Results 201 to 210 of about 6,436,336 (275)

Severe Infection Outcomes With SGLT2 Versus DPP‐4 Inhibitors in Type 2 Diabetes: A Systematic Review and Active‐Comparator Meta‐Analysis of Real‐World Cohorts

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
A systematic review of 18 real‐world cohorts found no increased average risk of severe infection with SGLT2 inhibitors versus DPP‐4 inhibitors. Lower pneumonia and sepsis estimates were heterogeneous and of very low certainty; two unpooled hospitalisation estimates were of low certainty. None should be read as infection prevention.
Yung‐Ming Huang   +4 more
wiley   +1 more source

Bacteremia in horses undergoing routine dental prophylaxis: Before, during, and after the procedure

open access: yesEquine Veterinary Journal, Volume 58, Issue 6, Page 1717-1725, November 2026.
Abstract Background Transient bacteremia after dental procedures is well‐documented in the literature, but the prevalence and clinical significance in horses remains largely unexplored. Objectives To assess whether routine dental prophylaxis in clinically healthy horses is associated with detection of bacteria in blood, using culture and 16S rDNA ...
Allison Dockery   +3 more
wiley   +1 more source

Hypertransaminasemia in hospitalized children: Insights from a national multicenter study by the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition

open access: yesJournal of Pediatric Gastroenterology and Nutrition, Volume 83, Issue 5, Page 841-848, November 2026.
Abstract Objectives Hypertransaminasemia is a frequent finding in hospitalized children with common pediatric illnesses, often considered a transitory phenomenon associated with systemic inflammation/injury. This study aims to assess the prevalence and causes of incidentally detected hypertransaminasemia in children admitted to general pediatric units ...
Angelo Di Giorgio   +21 more
wiley   +1 more source

Transoral Robotic Surgery in Head and Neck Oncology: A Scoping Review of Evidence, Technological Advancements, and Future Trajectories

open access: yesJournal of Surgical Oncology, Volume 134, Issue 6, Page 775-792, November 2026.
ABSTRACT Robotic surgery has transformed head and neck cancer (HNC) treatment. This scoping review synthesizes evidence on transoral robotic surgery (TORS), focusing on applications, limitations, and future directions. Following PRISMA‐ScR guidelines, this review used the PCC framework (Population: HNC patients; Concept: technological advancements ...
Anna Luíza Damaceno Araújo   +6 more
wiley   +1 more source

Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review summarizes current therapeutic and prophylactic strategies for global viral diseases, including vaccines, PrEP, direct‐acting antivirals, and emerging modalities such as CRISPR and siRNA. It highlights their clinical impact, ongoing challenges, and future priorities toward broader protection, improved delivery, and more effective antiviral ...
Sawar Khan   +12 more
wiley   +1 more source

Alzheimer's Disease: Mechanisms and Therapeutic Advances

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Alzheimer's disease involves Aβ/tau aggregation, neuroinflammation, BBB leakage, gut–brain dysfunction, and mitochondrial damage, causing neuronal loss. Nanodelivery enables combined small‐molecule and targeted therapies. Disease‐modifying biologics/chemicals, including anti‐Aβ antibodies, raise safety and access concerns. Exercise, cognitive training,
Gaoshuang Fu   +4 more
wiley   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy